Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
ZD Shi, K Pang, ZX Wu, Y Dong, L Hao… - … and Targeted Therapy, 2023 - nature.com
Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …
Molecular events in neuroendocrine prostate cancer development
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises
de novo only rarely; the disease predominantly develops from adenocarcinoma in response …
de novo only rarely; the disease predominantly develops from adenocarcinoma in response …
FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer
M Han, F Li, Y Zhang, P Dai, J He, Y Li, Y Zhu, J Zheng… - Cancer Cell, 2022 - cell.com
Prostate cancer adeno-to-neuroendocrine lineage transition has emerged as a mechanism
of targeted therapeutic resistance. Identifying the direct molecular drivers and develo** …
of targeted therapeutic resistance. Identifying the direct molecular drivers and develo** …
Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance
Emerging evidence indicates that various cancers can gain resistance to targeted therapies
by acquiring lineage plasticity. Although various genomic and transcriptomic aberrations …
by acquiring lineage plasticity. Although various genomic and transcriptomic aberrations …
ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression
N Li, Q Liu, Y Han, S Pei, B Cheng, J Xu, X Miao… - Nature …, 2022 - nature.com
Chronic inflammation and an immunosuppressive microenvironment promote prostate
cancer (PCa) progression and diminish the response to immune checkpoint blockade (ICB) …
cancer (PCa) progression and diminish the response to immune checkpoint blockade (ICB) …
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
L Merkens, V Sailer, D Lessel, E Janzen… - Journal of Experimental …, 2022 - Springer
Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on
increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against …
increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against …
[HTML][HTML] Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
Acquired resistance to tyrosine kinase inhibitors (TKI), such as osimertinib used to treat
EGFR-mutant lung adenocarcinomas, limits long-term efficacy and is frequently caused by …
EGFR-mutant lung adenocarcinomas, limits long-term efficacy and is frequently caused by …
Loss and revival of androgen receptor signaling in advanced prostate cancer
N Formaggio, MA Rubin, JP Theurillat - Oncogene, 2021 - nature.com
Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay
of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens …
of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens …
Going beyond Polycomb: EZH2 functions in prostate cancer
Abstract The Polycomb group (PcG) protein Enhancer of Zeste Homolog 2 (EZH2) is one of
the three core subunits of the Polycomb Repressive Complex 2 (PRC2). It harbors histone …
the three core subunits of the Polycomb Repressive Complex 2 (PRC2). It harbors histone …
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …